{"id":71431,"date":"2026-05-20T11:00:00","date_gmt":"2026-05-20T11:00:00","guid":{"rendered":"https:\/\/medsbase.com\/aicar-acadesine\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aicar-acadesine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/aicar-acadesine\/","title":{"rendered":"AICAR (Acadesine \/ AICA-Riboside)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 AICAR\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>AICAR<\/strong> (Acadesine \/ AICA-Riboside \/ 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside\u3001CAS 2627-69-2) \u306f\u6a19\u6e96\u7684\u306a\u4f4e\u5206\u5b50 <strong>AMPK\uff08AMP\u6d3b\u6027\u5316\u30d7\u30ed\u30c6\u30a4\u30f3\u30ad\u30ca\u30fc\u30bc\uff09\u6d3b\u6027\u5316\u5264<\/strong> used in metabolic, exercise-physiology, muscle, and cancer studies. AICAR is the cell-permeable riboside; once inside cells it is phosphorylated by adenosine kinase to the active nucleotide <strong>ZMP<\/strong> (5-aminoimidazole-4-carboxamide ribonucleotide), an AMP-mimetic that allosterically activates AMPK. Activated AMPK drives insulin-independent glucose uptake into skeletal muscle, increases fatty-acid oxidation, suppresses hepatic gluconeogenesis and de-novo lipogenesis, and inhibits mTORC1 \u2014 the canonical &#8220;exercise-in-a-pill&#8221; pharmacology. Supplied as lyophilized powder (\u226599% HPLC) for clinical studies use only. <em>\u30da\u30d7\u30c1\u30c9\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5316\u5408\u7269\u30af\u30e9\u30b9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u4f4e\u5206\u5b50\u30d7\u30ea\u30f3\u6838\u9178\u30a2\u30ca\u30ed\u30b0\uff1b\u7d30\u80de\u900f\u904e\u6027AMP\u6a21\u5023\u4f53\uff1bAMPK\u6d3b\u6027\u5316\u5264\uff1b; <em>\u30da\u30d7\u30c1\u30c9\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5316\u5b66\u540d<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">5-\u30a2\u30df\u30ce\u30a4\u30df\u30c0\u30be\u30fc\u30eb-4-\u30ab\u30eb\u30dc\u30ad\u30b5\u30df\u30c9-1-\u03b2-D-\u30ea\u30dc\u30d5\u30e9\u30ce\u30b7\u30c9\uff08\u5225\u540d\uff1aAcadesine\u3001AICA-Riboside\u3001NSC 105823\u3001Z-Riboside\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2627-69-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">258.23 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4f5c\u7528\u6a5f\u5e8f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d30\u80de\u900f\u904e\u6027\u306eAICA\u30ea\u30dc\u30b7\u30c9\u306f\u3001\u30a2\u30c7\u30ce\u30b7\u30f3\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u30fc\u3092\u4ecb\u3057\u3066\u53d6\u308a\u8fbc\u307e\u308c\u3001\u30a2\u30c7\u30ce\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u306b\u3088\u3063\u3066\u6d3b\u6027\u578b\u7d30\u80de\u5185\u4e00\u30ea\u30f3\u9178\u4f53\u3078\u3068\u30ea\u30f3\u9178\u5316\u3055\u308c\u307e\u3059 <strong>ZMP<\/strong> \uff085-\u30a2\u30df\u30ce\u30a4\u30df\u30c0\u30be\u30fc\u30eb-4-\u30ab\u30eb\u30dc\u30ad\u30b5\u30df\u30c9\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30c1\u30c9\uff09\u3002ZMP\u306fAMPK \u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u306eBateman\u30c9\u30e1\u30a4\u30f3\u3067AMP\u3092\u6a21\u5023\u3057\u3001\u7d30\u80de\u5185\u306eAMP:ATP\u6bd4\u306e\u5909\u5316\u3068\u306f\u7121\u95a2\u4fc2\u306bAMPK\u306e\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u6d3b\u6027\u5316\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u3002\u6d3b\u6027\u5316\u3055\u308c\u305fAMPK\u306f\u3001\u305d\u306e\u5f8c\u3001\u4e0b\u6d41\u306e\u4ee3\u8b1d\u30b9\u30a4\u30c3\u30c1\u30d7\u30ed\u30b0\u30e9\u30e0\uff08\u7570\u5316\u2191\u3001\u540c\u5316\u2193\uff09\u3092\u99c6\u52d5\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u8a72\u5f53\u306a\u3057\uff08\u4f4e\u5206\u5b50\u30d7\u30ea\u30f3\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30b7\u30c9 \u2014 \u30da\u30d7\u30c1\u30c9\u3067\u306f\u3042\u308a\u307e\u305b\u3093\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white crystalline powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u6c34\uff08\u7a4f\u3084\u304b\u306a\u52a0\u6e29\u3068\u64b9\u62cc\u3067\u7d0450 mg\/mL\uff09\u3001PBS\u3001\u304a\u3088\u3073DMSO\uff08100 mM\u4ee5\u4e0a\u306e\u30b9\u30c8\u30c3\u30af\uff09\u306b\u53ef\u6eb6\u3067\u3059\u3002\u6c34\u6eb6\u6db2\u306f\u5b8c\u5168\u306b\u6eb6\u89e3\u3055\u305b\u308b\u305f\u3081\u306b37 \u00b0C\u3078\u306e\u77ed\u6642\u9593\u52a0\u6e29\u304c\u5fc5\u8981\u306a\u5834\u5408\u304c\u3042\u308a\u307e\u3059\u3002\u7d30\u80de\u57f9\u990a\u7528\u306e\u4f5c\u696d\u6eb6\u6db2\u306f\u3001\u901a\u5e380.5\u20132 mM\u3067\u5897\u6b96\u57f9\u5730\u306b\u8abf\u88fd\u3055\u308c\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u77ed\u671f\u306e\u4f5c\u696d\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8 \u00b0C\uff1b\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f\u221220 \u00b0C\uff08\u221220 \u00b0C\u306736\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\uff09\u3002\u518d\u6eb6\u89e3\u3057\u305f\u6c34\u6eb6\u6db2\uff1a2\uff5e8 \u00b0C\u3001\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002DMSO\u30b9\u30c8\u30c3\u30af\uff1a\u221220 \u00b0C\u30011\u56de\u306e\u878d\u89e3\u306e\u307f\u4f7f\u7528\u3002\u9577\u6642\u9593\u306e\u5149\u66dd\u9732\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u4f5c\u696d\u6eb6\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306e\u7e70\u308a\u8fd4\u3057\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>AICAR\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>AICAR<\/strong> \uff085-\u30a2\u30df\u30ce\u30a4\u30df\u30c0\u30be\u30fc\u30eb-4-\u30ab\u30eb\u30dc\u30ad\u30b5\u30df\u30c9-1-\u03b2-D-\u30ea\u30dc\u30d5\u30e9\u30ce\u30b7\u30c9\u3001\u5225\u540d\u30a2\u30ab\u30c7\u30b7\u30f3\u3001AICA-\u30ea\u30dc\u30b7\u30c9\u3001NSC 105823\u3001Z-\u30ea\u30dc\u30b7\u30c9\uff1bCAS 2627-69-2\uff09\u306f\u3001\u4f4e\u5206\u5b50\u30d7\u30ea\u30f3\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\u985e\u4f3c\u4f53\u3067\u3042\u308a\u3001\u6d3b\u6027\u5316\u306e\u305f\u3081\u306e\u6700\u3082\u5f15\u7528\u3055\u308c\u308b\u85ac\u7406\u5b66\u7684\u30c4\u30fc\u30eb <strong>AMP\u6d3b\u6027\u5316\u30d7\u30ed\u30c6\u30a4\u30f3\u30ad\u30ca\u30fc\u30bc\uff08AMPK\uff09\u306e\u6d3b\u6027\u5316<\/strong> in cell-culture, primary-cell, and rodent in-vivo studies. It is <em>\u30da\u30d7\u30c1\u30c9\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/em> \u2014 \u5408\u6210\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\u3067\u3001\u5206\u5b50\u5f0fC<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub> and a molecular weight of 258.23 g\/mol. MedsBase stocks it in the same lyophilized-vial format as our peptide catalogue for convenience of reconstitution and dosing in mixed-protocol AMPK \/ metabolic \/ mitochondrial studies. AICAR was originally developed in the 1990s by Acadesine Inc. (later Schering-Plough) as a candidate cardioprotective agent for coronary artery bypass surgery \u2014 the compound completed Phase III trials but did not gain regulatory approval. Its pharmacological utility, however, has only expanded since: AICAR is now the standard reference compound for AMPK activation in published studies, and the AMPK pathway it engages has been implicated in nearly every major area of metabolic biology \u2014 insulin sensitivity, type-2 diabetes, fatty-acid oxidation, exercise physiology, muscle hypertrophy \/ atrophy, mitochondrial biogenesis, cancer metabolism, autophagy, and ageing. In published studies AICAR is described as an &#8220;exercise mimetic&#8221; because chronic administration in sedentary mice has been reported to drive a skeletal-muscle gene-expression signature, mitochondrial-biogenesis programme, and endurance-performance phenotype that broadly mimics the effects of voluntary wheel running \u2014 the original 2008 Narkar et\u00a0al. publication in <em>Cell<\/em> \uff08\u300cAMPK and PPAR\u03b4 Agonists Are Exercise Mimetics\u300d\uff09\u306f\u3053\u306e\u5206\u91ce\u3067\u6700\u3082\u5f15\u7528\u3055\u308c\u3066\u3044\u308b\u8ad6\u6587\u3067\u3059\u3002AICAR\u306f\u307e\u305f\u3001WADA\u7981\u6b62\u8868\uff08\u30af\u30e9\u30b9S4.5\u3001\u4ee3\u8b1d\u8abf\u7bc0\u85ac\uff09\u306b\u3082\u63b2\u8f09\u3055\u308c\u3066\u304a\u308a\u3001\u3053\u306e\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u5411\u4e0a\u306e\u53ef\u80fd\u6027\u304c\u3042\u308b\u305f\u3081\u3001\u30b9\u30dd\u30fc\u30c4\u306b\u304a\u3044\u3066\u5e38\u306b\u7981\u6b62\u3055\u308c\u3066\u3044\u307e\u3059\u3002 <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 ZMP\u3092\u4ecb\u3057\u305fAMPK\u306e\u7d30\u80de\u5185\u6d3b\u6027\u5316<\/h2>\n<p>AICAR\u306e\u4f5c\u7528\u6a5f\u5e8f\u306f\u3001\u3042\u3089\u3086\u308b\u85ac\u7406\u5b66\u7684AMPK\u6d3b\u6027\u5316\u85ac\u306e\u4e2d\u3067\u6700\u3082\u7279\u6027\u304c\u660e\u3089\u304b\u306b\u3055\u308c\u3066\u3044\u307e\u3059\uff1a<\/p>\n<ul>\n<li><strong>\u30a2\u30c7\u30ce\u30b7\u30f3\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u30fc\u3092\u4ecb\u3057\u305f\u7d30\u80de\u5185\u3078\u306e\u53d6\u308a\u8fbc\u307f<\/strong> \u2014 AICAR\uff08\u30ea\u30dc\u30b7\u30c9\uff09\u81ea\u4f53\u306f\u751f\u7269\u5b66\u7684\u306b\u4e0d\u6d3b\u6027\u3067\u3059\u3002\u5185\u5728\u6027\u30a2\u30c7\u30ce\u30b7\u30f3\u3084\u4ed6\u306e\u30d7\u30ea\u30f3\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\u3092\u5f62\u8cea\u819c\u3092\u901a\u3057\u3066\u8f38\u9001\u3059\u308b\u306e\u3068\u540c\u3058\u5e73\u8861\u578b\u304a\u3088\u3073\u6fc3\u7e2e\u578b\u30a2\u30c7\u30ce\u30b7\u30f3\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u30fc\uff08ENT1\u3001ENT2\u3001CNT2\u3001CNT3\uff09\u3092\u4ecb\u3057\u3066\u7d30\u80de\u5185\u306b\u53d6\u308a\u8fbc\u307e\u308c\u307e\u3059\u3002\u751f\u4f53\u5185\u3067\u306e\u7d44\u7e54\u5206\u5e03\u3068\u6fc3\u5ea6\u52d5\u614b\u306f\u3053\u308c\u3089\u306e\u30c8\u30e9\u30f3\u30b9\u30dd\u30fc\u30bf\u30fc\u306b\u3088\u3063\u3066\u5236\u5fa1\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><strong>\u30a2\u30c7\u30ce\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u306b\u3088\u308bZMP\u3078\u306e\u7d30\u80de\u5185\u30ea\u30f3\u9178\u5316<\/strong> \u2014 \u7d30\u80de\u5185\u306b\u5165\u308b\u3068\u3001AICAR\u306f <strong>\u30a2\u30c7\u30ce\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\uff08AK\uff09<\/strong> on its 5\u2032-hydroxyl, generating the active metabolite ZMP (5-aminoimidazole-4-carboxamide ribonucleotide). ZMP is the immediate AMP analogue and is the species that actually engages AMPK. Adenosine kinase activity is therefore the rate-limiting step for AICAR pharmacology in any given tissue \u2014 protocols that use AK-deficient cells or AK inhibitors confirm that ZMP, not AICAR itself, is the active species.<\/li>\n<li><strong>AMPK\u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u3067\u306e\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u6d3b\u6027\u5316<\/strong> \u2014 ZMP\u306f\u3001\u4f4e\u30a8\u30cd\u30eb\u30ae\u30fc\u6761\u4ef6\u4e0b\u3067\u5185\u5728\u6027AMP\u304c\u5360\u6709\u3059\u308bAMPK\u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u4e0a\u306eBateman\u30c9\u30e1\u30a4\u30f3CBS\u90e8\u4f4d\u3068\u540c\u3058\u90e8\u4f4d\u306b\u7d50\u5408\u3057\u307e\u3059\u3002ZMP\u7d50\u5408\u306f\u3001AMPK\u306b\u5bfe\u3057\u3066\u4ee5\u4e0b\u306e3\u3064\u306e\u53ce\u675f\u7684\u306a\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u52b9\u679c\u3092\u751f\u307f\u51fa\u3057\u307e\u3059\uff1a(1) \u89e6\u5a92\u6d3b\u6027\u306e\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u523a\u6fc0\u3001(2) AMPK\u03b1\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u4e0a\u306eThr172\u30ea\u30f3\u9178\u5316\u306ePP2C\u8131\u30ea\u30f3\u9178\u5316\u304b\u3089\u306e\u4fdd\u8b77\u3001\u304a\u3088\u3073(3) \u4e0a\u6d41\u30ad\u30ca\u30fc\u30bcLKB1\u304a\u3088\u3073CaMKK2\u306b\u3088\u308bThr172\u30ea\u30f3\u9178\u5316\u306e\u4fc3\u9032\u3002\u305d\u306e\u7d50\u679c\u3001\u5b9f\u969b\u306e\u7d30\u80de\u5185AMP:ATP\u6bd4\u306e\u5909\u5316\u3068\u306f\u7121\u95a2\u4fc2\u306b\u3001\u6301\u7d9a\u7684\u3067\u9ad8\u30ec\u30d9\u30eb\u306eAMPK\u6d3b\u6027\u5316\u304c\u9054\u6210\u3055\u308c\u307e\u3059\u3002<\/li>\n<li><strong>\u4e0b\u6d41\u306e\u4ee3\u8b1d\u30b9\u30a4\u30c3\u30c1 \u2014 \u7570\u5316\u4f5c\u7528\u306e\u4ea2\u9032<\/strong> \u2014 Activated AMPK phosphorylates a large set of metabolic effectors that drive the catabolic \/ energy-generating programme: ACC (acetyl-CoA carboxylase, on Ser79 and Ser212) \u2014 relieving malonyl-CoA inhibition of CPT-I and allowing long-chain fatty acids into the mitochondria for \u03b2-oxidation; HSL (hormone-sensitive lipase) \u2014 increasing adipocyte lipolysis; TBC1D1 \u2014 driving insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle; PGC-1\u03b1 \u2014 driving mitochondrial biogenesis. The skeletal-muscle glucose-uptake effect is the most-cited functional readout in AMPK studies.<\/li>\n<li><strong>\u4e0b\u6d41\u306e\u4ee3\u8b1d\u30b9\u30a4\u30c3\u30c1 \u2014 \u540c\u5316\u4f5c\u7528\u306e\u6291\u5236<\/strong> \u2014 \u6d3b\u6027\u5316\u3055\u308c\u305fAMPK\u306f\u3001\u540c\u5316\/\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u7d4c\u8def\u3092\u540c\u6642\u306b\u6291\u5236\u3057\u307e\u3059\u3002TSC2\u304a\u3088\u3073Raptor\u306e\u30ea\u30f3\u9178\u5316\u306fmTORC1\u3092\u963b\u5bb3\u3057\u3001\u30bf\u30f3\u30d1\u30af\u8cea\u5408\u6210\u3092\u6291\u5236\u3057\u3066\u30aa\u30fc\u30c8\u30d5\u30a1\u30b8\u30fc\u3092\u8a98\u767a\u3057\u307e\u3059\u3002HMG-CoA\u30ec\u30c0\u30af\u30bf\u30fc\u30bc\u306e\u30ea\u30f3\u9178\u5316\u306f\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u5408\u6210\u3092\u6291\u5236\u3057\u307e\u3059\u3002SREBP1c\u306e\u30ea\u30f3\u9178\u5316\u306f\u809d\u81d3\u306ede novo\u8102\u8cea\u5408\u6210\u3092\u6291\u5236\u3057\u307e\u3059\u3002PFKFB3\u304a\u3088\u3073ACC\u306e\u30ea\u30f3\u9178\u5316\u306f\u30b0\u30ea\u30b3\u30fc\u30b2\u30f3\u304a\u3088\u3073\u8102\u80aa\u9178\u5408\u6210\u3092\u6291\u5236\u3057\u307e\u3059\u3002\u3053\u306e\u7570\u5316\u4ea2\u9032\/\u540c\u5316\u6291\u5236\u306e\u30b9\u30a4\u30c3\u30c1\u306e\u7d44\u307f\u5408\u308f\u305b\u304c\u3001\u6a19\u6e96\u7684\u306aAMPK\u85ac\u7406\u5b66\u3067\u3059\u3002<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of AICAR is broadly favourable for use \u2014 oral bioavailability is modest but workable, intraperitoneal administration in rodents produces reliable systemic exposure within 30 minutes, and the plasma half-life of the parent riboside is on the order of 90 minutes (the half-life of the intracellular ZMP metabolite is longer, sustaining AMPK activation for several hours after a single bolus dose). Typical in-vivo rodent protocols use 250\u2013500\u00a0mg\/kg administered IP daily; high doses (1\u00a0g\/kg) have been used in some published muscle-physiology studies. In-vitro cell culture work typically uses 0.5\u20132\u00a0mM in growth medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AICAR is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>AMPK\u85ac\u7406\u5b66 \u2014 \u6a19\u6e96\u7684\u306a\u53c2\u7167\u6d3b\u6027\u5316\u85ac<\/strong> \u2014 by far the most-cited small-molecule AMPK activator in the published literature; standard tool compound for any new AMPK-pathway studies; reference compound against which all newer direct AMPK activators (A769662, MK-8722, PF-739, O304, the metformin class) are benchmarked<\/li>\n<li><strong>\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3068\u9aa8\u683c\u7b4b\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u53d6\u308a\u8fbc\u307f<\/strong> \u2014 AICAR drives insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle via the AMPK-TBC1D1 axis; widely used in studies on type-2 diabetes, insulin-resistance reversal, and skeletal-muscle metabolic flexibility<\/li>\n<li><strong>Exercise mimetic and endurance studies<\/strong> \u2014 Narkar\u3089\uff082008\u5e74\u3001, <em>Cell<\/em>\u300cAMPK and PPAR\u03b4 Agonists Are Exercise Mimetics\u300d\u306e\u67a0\u7d44\u307f\u306f\u3001AICAR\u306b\u95a2\u3059\u308b\u6700\u3082\u5f15\u7528\u3055\u308c\u3066\u3044\u308b\u8ad6\u6587\u3067\u3042\u308a\u3001\u516c\u8868\u3055\u308c\u3066\u3044\u308b\u3052\u3063\u6b6f\u985e\u306e\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u3001\u975e\u904b\u52d5\u30de\u30a6\u30b9\u3078\u306e4\u9031\u9593\u306eAICAR\u6295\u4e0e\u306b\u3088\u308a\u3001\u6301\u4e45\u529b\u306e\u5411\u4e0a\u3001\u9045\u7b4b\uff08\u30bf\u30a4\u30d7I\uff09\u7dda\u7dad\u3078\u306e\u5909\u63db\u3001\u304a\u3088\u3073\u9178\u5316\u80fd\u529b\u306e\u6539\u5584\u304c\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/li>\n<li><strong>\u809d\u7cd6\u65b0\u751f\u304a\u3088\u3073\u8102\u8cea\u65b0\u751f\u306e\u6291\u5236<\/strong> \u2014 AICAR suppresses hepatic glucose output via AMPK-mediated phosphorylation of transcriptional co-activators (CRTC2, HNF4\u03b1); also suppresses hepatic de-novo lipogenesis via SREBP1c phosphorylation; used in non-alcoholic fatty liver disease (NAFLD) and metabolic-dysfunction-associated steatohepatitis (MASH) preclinical studies<\/li>\n<li><strong>Fatty-acid oxidation studies<\/strong> \u2014 AICAR\u306fACC\u3092\u30ea\u30f3\u9178\u5316\u3057\u3001\u30de\u30ed\u30cb\u30ebCoA\u306b\u3088\u308bCPT-I\u963b\u5bb3\u3092\u89e3\u9664\u3057\u3001\u9577\u9396\u8102\u80aa\u9178\u3092\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u3078\u3068\u8f38\u9001\u3057\u3066\u03b2\u9178\u5316\u3092\u4fc3\u9032\u3057\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u521d\u4ee3\u809d\u7d30\u80de\u3001\u5fc3\u7b4b\u7d30\u80de\u3001\u304a\u3088\u3073\u9aa8\u683c\u7b4b\u7b4b\u7ba1\u306b\u304a\u3051\u308b\u8102\u80aa\u9178\u9178\u5316\u3092\u4ea2\u9032\u3055\u305b\u308b\u5178\u578b\u7684\u306a\u85ac\u7406\u5b66\u7684\u4ecb\u5165\u3067\u3059\u3002<\/li>\n<li><strong>Cancer metabolism studies<\/strong> \u2014 many cancer cells display elevated lipogenesis (via SREBP1c) and elevated mTORC1 signalling; AICAR suppresses both via AMPK activation and has been investigated in published studies on acute lymphoblastic leukaemia (the historical original indication for Acadesine), prostate cancer, breast cancer, and other tumour models<\/li>\n<li><strong>Autophagy and mTORC1-inhibition studies<\/strong> \u2014 AICAR triggers autophagy via dual phosphorylation of TSC2 (Ser1387) and Raptor (Ser792), both of which inhibit mTORC1; used as a pharmacological intervention in autophagy-induction studies alongside rapamycin and starvation models<\/li>\n<li><strong>Mitochondrial biogenesis studies<\/strong> \u2014 AICAR\u306fPGC-1\u03b1\u306e\u767a\u73fe\u3068\u6d3b\u6027\u3092\u4fc3\u9032\u3057\u3001\u9aa8\u683c\u7b4b\u304a\u3088\u3073\u8910\u8272\u8102\u80aa\u7d44\u7e54\u306b\u304a\u3051\u308b\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u5408\u6210\u3092\u5897\u52a0\u3055\u305b\u307e\u3059\u3002\u3053\u308c\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> \uff08\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u7531\u6765AMPK\u6d3b\u6027\u5316\u30da\u30d7\u30c1\u30c9\uff09\u3092\u3001AMPK\u7d4c\u8def\u306e\u5197\u9577\u6027\u3092\u63a2\u308b\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u4f7f\u7528\u3057\u307e\u3059\u3002<\/li>\n<li><strong>Cardioprotection studies<\/strong> \u2014 the original clinical indication; AICAR has been used in ischaemia-reperfusion injury models and the cardiac-surgery cardioprotection paradigm; preclinical studies continues despite Phase III not gaining approval<\/li>\n<\/ul>\n<p>AMPK\/NAD\u306b\u95a2\u3059\u308b\u3088\u308a\u5e83\u7bc4\u306a\u6587\u8108\u306b\u3064\u3044\u3066\u306f<sup>+<\/sup> \/ metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> \uff08\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u7531\u6765\u30da\u30d7\u30c1\u30c9AMPK\u6d3b\u6027\u5316\u56e0\u5b50 \u2014 \u6700\u3082\u8fd1\u3044\u30da\u30d7\u30c1\u30c9\u985e\u4f3c\u4f53\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/5-amino-1mq\/\">5-Amino-1MQ<\/a> \uff08NNMT\u963b\u5bb3\u5264\uff1b\u88dc\u5b8c\u7684\u306aNAD<sup>+<\/sup>-\u524d\u99c6\u4f53\u7bc0\u7d04\u30a2\u30d7\u30ed\u30fc\u30c1\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD<sup>+<\/sup><\/a> \uff08\u9178\u5316\u578b\u30b8\u30cc\u30af\u30ec\u30aa\u30c1\u30c9\u88dc\u9175\u7d20\u3001\u4e2d\u5fc3\u7684\u306a\u96fb\u5b50\u4f1d\u9054\u57fa\u8cea\uff09\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/l-carnitine\/\">L-\u30ab\u30eb\u30cb\u30c1\u30f3<\/a> \uff08\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u9577\u9396\u8102\u80aa\u9178\u30b7\u30e3\u30c8\u30eb\uff09\u3002\u5168 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">peptides &amp; compounds catalog<\/a> \u95a2\u9023\u5316\u5408\u7269\u306b\u3064\u3044\u3066\u306f\u3001\u3042\u308b\u3044\u306f\u53b3\u9078\u3055\u308c\u305f <a href=\"https:\/\/medsbase.com\/ja\/best-longevity-peptides\/\">longevity compounds<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> \u30cf\u30d6\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks AICAR in a single lyophilized vial size calibrated to typical in-vivo and high-throughput in-vitro protocols. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 single-cohort in-vivo rodent dosing (250\u2013500\u00a0mg\/kg IP daily for 2\u20134 weeks covers a 30-g mouse cohort with one 50\u00a0mg vial per ~2\u20133 doses), high-throughput in-vitro AMPK-activation panels (0.5\u20132\u00a0mM working concentrations), reconstitution-and-dose-titration work, primary-hepatocyte \/ myotube fatty-acid-oxidation panels<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 50\u00a0mg vial format provides a convenient dosing unit for most published in-vivo rodent protocols and supports the 0.5\u20132\u00a0mM working concentrations used in cell-culture AMPK-activation studies. The 30-vial pack is the more economical purchase per-mg for extended-cycle or large-cohort protocols (4\u20138 week chronic dosing, multi-cohort exercise-mimetic studies). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>\u6bd4\u8f03 \u2014 AICAR vs MOTS-c<\/h2>\n<p>AICAR\u3068 <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> are the two most-studied AMPK-activating compounds in this catalogue, and they target the AMPK pathway via mechanistically distinct routes. AICAR is a small-molecule cell-permeable AMP-mimetic that drives AMPK activation directly at the \u03b3-subunit. MOTS-c is a mitochondrial-derived 16-amino-acid peptide that translocates to the nucleus under metabolic stress and activates AMPK indirectly through a folate-pathway \/ methionine-cycle intermediate (AICAR-like increase in cellular AICAR \/ ZMP levels). The two compounds are mechanistically complementary in published combination studies, and the comparison illustrates one of the most-studied &#8220;small-molecule vs peptide&#8221; dyads in AMPK biology. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AICAR<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u5316\u5b66\u5206\u985e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5c0f\u5206\u5b50\u30d7\u30ea\u30f3\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\uff08\u7d30\u80de\u900f\u904e\u6027AMP\u6a21\u5023\u4f53\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u7531\u676516\u6b8b\u57fa\u30da\u30d7\u30c1\u30c9\uff08MTHFD2L\u7d4c\u8def \/ AICAR\u69d8\u84c4\u7a4d\u6a5f\u69cb\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">258.23 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2,174 g\/mol\uff0816\u6b8b\u57fa\u30da\u30d7\u30c1\u30c9\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>AMPK\u3078\u306e\u7d4c\u8def<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u76f4\u63a5\u7684 \u2014 \u7d30\u80de\u5185\u3067ZMP\u306b\u30ea\u30f3\u9178\u5316\u3055\u308c\u3001AMPK \u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u306eBateman\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\uff08AMP\u6a21\u5023\u4f53\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u9593\u63a5\u7684 \u2014 \u8449\u9178\/\u30e1\u30c1\u30aa\u30cb\u30f3\u56de\u8def\u3092\u652a\u4e71\u3057\u3001\u7d30\u80de\u5185AICAR\/ZMP\u3092\u4e0a\u6607\u3055\u305b\u3001\u540c\u3058\u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u306e\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u90e8\u4f4d\u3092\u4ecb\u3057\u3066AMPK\u3092\u6d3b\u6027\u5316<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u904b\u52d5\u6a21\u5023\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3001\u809d\u7cd6\u65b0\u751f\u3001\u764c\u4ee3\u8b1d\u3001\u30aa\u30fc\u30c8\u30d5\u30a1\u30b8\u30fc\u3001\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u5408\u6210<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3001\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u7269\u5b66\u3001\u52a0\u9f62\u306b\u4f34\u3046\u4ee3\u8b1d\u4f4e\u4e0b\u3001\u9577\u5bff\u3001\u30da\u30d7\u30c1\u30c9\u8ef8\u85ac\u7406\u5b66<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8840\u6f3f\u4e2d\u5b89\u5b9a\u6027<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0490\u5206\u306e\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f\uff08\u89aa\u30ea\u30dc\u30b7\u30c9\uff09\uff1b\u7d30\u80de\u5185ZMP\u306f1\u56de\u306e\u30dc\u30fc\u30e9\u30b9\u6295\u4e0e\u3042\u305f\u308a\u6570\u6642\u9593\u52b9\u679c\u3092\u6301\u7d9a\u3057\u307e\u3059<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short \u2014 minutes of plasma half-life unprotected; supports IP \/ SC dosing in studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u3052\u3063\u6b6f\u985e\u3067\u306f250\uff5e500 mg\/kg\u3092IP\u3067\u6bce\u65e5\u6295\u4e0e\uff08\u7b4b\u8089\u751f\u7406\u5b66\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u6642\u62981 g\/kg\uff09\uff1b\u7d30\u80de\u57f9\u990a\u3067\u306f0.5\uff5e2 mM<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u3052\u3063\u6b6f\u985e\u3067\u306f0.5\uff5e5 mg\/kg\u3092IP\/SC\u3067\u6295\u4e0e<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u9078\u629e\u6027\uff0f\u30aa\u30d5\u30bf\u30fc\u30b2\u30c3\u30c8\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5b8c\u5168\u306b\u306f\u9078\u629e\u7684\u3067\u306f\u3042\u308a\u307e\u305b\u3093 \u2014 \u9ad8\u7528\u91cf\u3067\u306fZMP\u306f\u30a2\u30c7\u30ce\u30b7\u30f3\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3001\u30d5\u30eb\u30af\u30c8\u30fc\u30b9-1,6-\u30d3\u30b9\u30db\u30b9\u30d5\u30a1\u30bf\u30fc\u30bc\u3001AMP\u30c7\u30a2\u30df\u30ca\u30fc\u30bc\u306b\u3082\u5f71\u97ff\u3057\u307e\u3059<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30da\u30d7\u30c1\u30c9\u30af\u30e9\u30b9\u306e\u9078\u629e\u6027 \u2014 \u6587\u732e\u4e0a\u306e\u30aa\u30d5\u30bf\u30fc\u30b2\u30c3\u30c8\u306e\u5c0f\u5206\u5b50\u53d7\u5bb9\u4f53\u3078\u306e\u5f71\u97ff\u306f\u5c11\u306a\u3044\u3067\u3059\u304c\u3001\u53d7\u5bb9\u4f53\u306e\u6b63\u4f53\u306f\u8abf\u67fb\u4e2d\u3067\u3059<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u627f\u8a8d\u72b6\u6cc1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u81e8\u5e8a\u627f\u8a8d\u306f\u3042\u308a\u307e\u305b\u3093\uff08\u30a2\u30ab\u30c7\u30b7\u30f3\u306eCABG\u306b\u5bfe\u3059\u308b\u7b2cIII\u76f8\u8a66\u9a13\u306f\u627f\u8a8d\u3092\u5f97\u3089\u308c\u307e\u305b\u3093\u3067\u3057\u305f\uff09\uff1bWADA\u7981\u6b62\u8868S4.5\uff08\u30b9\u30dd\u30fc\u30c4\u3067\u306f\u5e38\u6642\u7981\u6b62\u3055\u308c\u3066\u3044\u307e\u3059\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No clinical approval; studies-only peptide<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on direct, high-magnitude AMPK activation with the canonical small-molecule reference tool, AICAR is the standard compound. For studies focused on peptide-class AMPK activation, mitochondrial-derived signalling, or longevity-axis peptide pharmacology, <a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a> \u3088\u308a\u6a19\u7684\u3092\u7d5e\u3063\u305f\u30c4\u30fc\u30eb\u3067\u3059\u3002\u3053\u3061\u3089\u3082\u3054\u89a7\u304f\u3060\u3055\u3044 <a href=\"https:\/\/medsbase.com\/ja\/5-amino-1mq\/\">5-Amino-1MQ<\/a> for NAD-axis precursor-sparing studies, <a href=\"https:\/\/medsbase.com\/ja\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-binding mitochondrial-targeted studies, and <a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD<sup>+<\/sup><\/a> \u76f4\u63a5\u7684\u306aNAD\u30d7\u30fc\u30eb\u88dc\u5145\u5411\u3051\u3002 <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 BAC\u6c34\u304c\u5fc5\u8981\u3067\u3059\u304b\uff1f<\/strong> \u51cd\u7d50\u4e7e\u71e5\u54c1\u306e\u5fa9\u5143\u306b\u306f\u6ec5\u83cc\u9759\u83cc\u6c34\u304c\u5fc5\u8981\u3067\u3059\u3002\u672c\u88fd\u54c1\u3068\u4f75\u305b\u3066\u5f53\u793e\u306e <a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 30 mL\u30de\u30eb\u30c1\u30c9\u30fc\u30ba\u30d0\u30a4\u30a2\u30eb\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u3001USP\u30b0\u30ec\u30fc\u30c9\u3002<\/div>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u9593\u306e\u4f7f\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8 \u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u9577\u671f\u9593\u4fdd\u7ba1\u306e\u5834\u5408\u306f\u3001\u672a\u958b\u5c01\u306e\u30d0\u30a4\u30a2\u30eb\u3092\u221220 \u00b0C\u3067\u51b7\u51cd\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u221220 \u00b0C\u306736\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\u30012\uff5e8 \u00b0C\u306712\u304b\u6708\u4ee5\u4e0a\u5b89\u5b9a\uff09\u3002\u51cd\u7d50\u4e7e\u71e5AICAR\u306f\u3001\u307b\u3068\u3093\u3069\u306e\u51cd\u7d50\u4e7e\u71e5\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u306f\u308b\u304b\u306b\u5b89\u5b9a\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u4f4e\u5206\u5b50\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\u306b\u306f\u52a0\u6c34\u5206\u89e3\u3055\u308c\u308b\u30a2\u30df\u30c9\u7d50\u5408\u3084\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u304c\u5b58\u5728\u3057\u306a\u3044\u305f\u3081\u3067\u3059\u3002\u76f4\u5c04\u65e5\u5149\u3078\u306e\u9577\u6642\u9593\u306e\u66b4\u9732\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> 50 mg\u306e\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u3001\u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3001\u6ec5\u83cc\u6c34\u3001\u307e\u305f\u306f\u6ec5\u83ccPBS 1.0 mL\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5185\u58c1\u306b\u6cbf\u3063\u3066\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u3053\u308c\u306b\u3088\u308a50 mg\/mL\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\uff08\u7d04193 mM\uff09\u304c\u5f97\u3089\u308c\u307e\u3059\u3002\u3088\u308a\u5e0c\u91c8\u3057\u305f\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u30012.5 mL\u306720 mg\/mL\uff08\u7d0477 mM\uff09\u30015.0 mL\u306710 mg\/mL\uff08\u7d0439 mM\uff09\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u304c\u5f97\u3089\u308c\u307e\u3059\u3002AICAR\u306f\u5ba4\u6e29\u3067\u7a4f\u3084\u304b\u306b\u65cb\u56de\u3055\u305b\u308b\u3053\u3068\u3067\u901f\u3084\u304b\u306b\u6eb6\u89e3\u3057\u307e\u3059\u3002\u51b7\u8535\u4fdd\u7ba1\u306b\u3088\u308a\u6b8b\u7559\u7d50\u6676\u304c\u307f\u3089\u308c\u308b\u5834\u5408\u306f\u300137 \u00b0C\u306b\u77ed\u6642\u9593\u52a0\u6e29\u3059\u308b\u3068\u6eb6\u89e3\u304c\u4fc3\u9032\u3055\u308c\u307e\u3059\u3002in vitro\u7d30\u80de\u57f9\u990a\u5b9f\u9a13\u3067\u306f\u3001DMSO\u3082\u9069\u3057\u305f\u518d\u69cb\u6210\u6eb6\u5a92\u3067\u3059\uff08\u6700\u5927200 mM\u306e\u30b9\u30c8\u30c3\u30af\u306b\u8abf\u88fd\u53ef\u80fd\uff09\u3002\u3054\u4f7f\u7528\u76f4\u524d\u306b\u6c34\u6027\u57f9\u5730\u306b\u5e0c\u91c8\u3057\u3001\u5897\u6b96\u57f9\u5730\u4e2d\u306e\u6700\u7d42\u6fc3\u5ea60.5\uff5e2 mM\u3092\u76ee\u5b89\u306b\u8abf\u6574\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6c34\u6027\u30d0\u30c3\u30d5\u30a1\u30fc\u3067\u518d\u69cb\u6210\u5f8c\u306f\u3001\u30d0\u30a4\u30a2\u30eb\u30922\uff5e8 \u00b0C\u3067\u4fdd\u7ba1\u3057\u300130\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6fc1\u308a\u3001\u7c92\u5b50\u72b6\u7269\u8cea\u3001\u307e\u305f\u306f\u9855\u8457\u306a\u8272\u5909\u5316\u304c\u8a8d\u3081\u3089\u308c\u305f\u5834\u5408\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>AICAR\u306f\u30da\u30d7\u30c1\u30c9\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u3044\u3044\u3048\u3002AICAR\u306f\u4f4e\u5206\u5b50\u30d7\u30ea\u30f3\u30ea\u30dc\u30cc\u30af\u30ec\u30aa\u30b7\u30c9\u985e\u4f3c\u4f53\uff08\u5206\u5b50\u91cf 258.23 g\/mol\uff09\u3067\u3042\u308a\u3001, <em>\u3057\u307e\u305b\u3093<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/ja\/5-amino-1mq\/\">5-Amino-1MQ<\/a>, <a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD<sup>+<\/sup><\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/l-carnitine\/\">L-\u30ab\u30eb\u30cb\u30c1\u30f3<\/a> because it serves a complementary role in mitochondrial \/ metabolic \/ AMPK-axis studies and is supplied in the same lyophilized vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>AICAR\u3001Acadesine\u3001AICA-Riboside\u3001ZMP\u306e\u9055\u3044\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>AICAR\u3001Acadesine\u3001AICA-Riboside\u3001NSC 105823\u3001Z-Riboside\u306f <em>\u3059\u3079\u3066\u540c\u3058\u5316\u5408\u7269\u3067\u3042\u308a\u3001<\/em> \u2014 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside\uff08\u7d30\u80de\u900f\u904e\u6027\u30ea\u30dc\u30b7\u30c9\u3001CAS 2627-69-2\uff09\u306e5\u901a\u308a\u306e\u7570\u306a\u308b\u540d\u79f0\u3067\u3059\u3002 <strong>ZMP<\/strong> is a different compound \u2014 the intracellular monophosphate (5-aminoimidazole-4-carboxamide ribonucleotide), generated by adenosine kinase from the riboside once it has entered the cell. ZMP is the actual AMP-mimetic that engages AMPK; the riboside itself (AICAR) is the cell-permeable pro-drug. Studies suppliers sell the riboside because it is cell-permeable; the monophosphate (ZMP) does not cross the plasma membrane. <\/p>\n<h3>AICAR\u306f\u306a\u305c\u300c\u904b\u52d5\u6a21\u5023\u85ac\u300d\u3068\u547c\u3070\u308c\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Narkar\u3089\uff082008\uff09 <em>Cell<\/em> \u8ad6\u6587\u300cAMPK and PPAR\u03b4 Agonists Are Exercise Mimetics\u300d\u3067\u306f\u3001\u5ea7\u308a\u304c\u3061\u306a\u30de\u30a6\u30b9\u306bAICAR\u30924\u9031\u9593\u6295\u4e0e\uff08500 mg\/kg\/\u65e5 \u8179\u8154\u5185\u6295\u4e0e\uff09\u3057\u305f\u7d50\u679c\u3001\u9aa8\u683c\u7b4b\u306e\u907a\u4f1d\u5b50\u767a\u73fe\u30b7\u30b0\u30cd\u30c1\u30e3\u30fc\u3001\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u5408\u6210\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3001\u9045\u7b4b\uff08\u30bf\u30a4\u30d7I\uff09\u9178\u5316\u7dda\u7dad\u3078\u306e\u7dda\u7dad\u30bf\u30a4\u30d7\u79fb\u884c\u3001\u6301\u4e45\u529b\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u8868\u73fe\u578b\u304c\u3001\u672a\u51e6\u7406\u30de\u30a6\u30b9\u306b\u304a\u3051\u308b\u81ea\u767a\u7684\u30db\u30a4\u30fc\u30eb\u30e9\u30f3\u30cb\u30f3\u30b0\u306e\u52b9\u679c\u3092\u5e83\u7bc4\u306b\u6a21\u5023\u3057\u305f\u3068\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u300c\u30a8\u30af\u30b5\u30b5\u30a4\u30ba\u30fb\u30a4\u30f3\u30fb\u30a2\u30fb\u30d4\u30eb\u300d\u3068\u3044\u3046\u8868\u73fe\u306f\u3053\u306e\u8ad6\u6587\u306b\u7531\u6765\u3057\u307e\u3059\u3002AICAR\u304cWADA\u7981\u6b62\u8868\u306b\u63b2\u8f09\u3055\u308c\u3066\u3044\u308b\u306e\u306f\u3001\u3053\u308c\u3089\u306e\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u5411\u4e0a\u6240\u898b\u3082\u4e00\u56e0\u3067\u3059\u3002 <\/p>\n<h3>What published dose ranges have been used in mouse and rat studies?<\/h3>\n<p>The most-cited mouse-protocol dose is 250\u2013500\u00a0mg\/kg IP daily, administered for 2\u20134 weeks. The endurance-phenotype Narkar et\u00a0al. protocol used 500\u00a0mg\/kg\/d IP for 4 weeks. Higher doses (up to 1\u00a0g\/kg) have been used in some muscle-physiology studies. Rat protocols are similar (250\u2013500\u00a0mg\/kg IP). In-vitro cell-culture work typically uses 0.5\u20132\u00a0mM AICAR in growth medium. Users should consult primary literature (Narkar et\u00a0al. 2008; Corton et\u00a0al. 1995 original AMPK-activation paper; Merrill et\u00a0al. 1997 skeletal-muscle glucose-uptake paper) for species-, model-, and endpoint-specific dosing guidance. <\/p>\n<h3>AICAR\u306eWADA\u898f\u5236\u72b6\u6cc1\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>AICAR \/ Acadesine is listed on the World Anti-Doping Agency (WADA) Prohibited List under class S4.5 (Hormone and Metabolic Modulators) and is prohibited in sport at all times \u2014 both in-competition and out-of-competition. The basis is the exercise-mimetic endurance-phenotype finding. Users conducting human-subject studies with AICAR need to be aware of this status (in addition to regulatory requirements for any unapproved drug). For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>AMPK\u6d3b\u6027\u5316\u5264\u3068\u3057\u3066\u3001AICAR\u3068\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u306f\u3069\u306e\u3088\u3046\u306b\u6bd4\u8f03\u3055\u308c\u307e\u3059\u304b\uff1f<\/h3>\n<p>AICAR\u3068\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u306f\u3069\u3061\u3089\u3082AMPK\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u304c\u3001\u5b8c\u5168\u306b\u7570\u306a\u308b\u4e0a\u6d41\u7d4c\u8def\u3092\u4ecb\u3057\u307e\u3059\u3002AICAR\uff08\u7d30\u80de\u5185\u3067ZMP\u306b\u5909\u63db\u5f8c\uff09\u306f\u3001 <em>\u76f4\u63a5\u7684\u306a<\/em> AMP\u6a21\u5023\u7269\u8cea\u3067\u3001AMPK\u306e\u03b3\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8Bateman\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\u3057\u307e\u3059\u3002\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u306f\u3001 <em>\u9593\u63a5\u7684<\/em> AMPK\u6d3b\u6027\u5316\u5264 \u2014 \u672c\u5264\u306f\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u8907\u5408\u4f53I\u3092\u963b\u5bb3\u3057\u3001ATP\u3092\u4f4e\u4e0b\u3055\u305bAMP:ATP\u6bd4\u3092\u4e0a\u6607\u3055\u305b\u308b\u3053\u3068\u3067\u3001\u5929\u7136\u306eAMP\u7d50\u5408\u30e1\u30ab\u30cb\u30ba\u30e0\u3092\u4ecb\u3057\u3066\u4e8c\u6b21\u7684\u306bAMPK\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u3053\u308c\u30892\u3064\u306e\u5316\u5408\u7269\u306fAMPK\u7d4c\u8def\u306e\u7570\u306a\u308b\u5c64\u3092\u63a2\u308a\u307e\u3059\u3002AICAR\/ZMP\u306f\u5b9f\u969b\u306e\u30a8\u30cd\u30eb\u30ae\u30fc\u30b9\u30c8\u30ec\u30b9\u306e\u5fc5\u8981\u6027\u3092\u56de\u907f\u3059\u308b\u4e00\u65b9\u3001\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u306f\u5929\u7136\u306e\u30a8\u30cd\u30eb\u30ae\u30fc\u611f\u77e5\u5206\u679d\u306b\u95a2\u4e0e\u3057\u307e\u3059\u3002\u65b0\u3057\u3044\u76f4\u63a5AMPK\u6d3b\u6027\u5316\u5264\uff08A769662\u3001MK-8722\u3001PF-739\u3001O304\uff09\u306f\u3001\u7b2c3\u306e\u90e8\u4f4d\uff08ADaM\/\u03b2\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u30a2\u30ed\u30b9\u30c6\u30ea\u30c3\u30af\u30dd\u30b1\u30c3\u30c8\uff09\u306b\u7d50\u5408\u3057\u3001AICAR\u3084\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u3088\u308a\u3082\u512a\u308c\u305f\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0\u9078\u629e\u6027\u3092\u793a\u3057\u307e\u3059\u3002 <\/p>\n<h3>AICAR\u306fMOTS-c\u3001NAD<sup>+<\/sup>, or 5-Amino-1MQ in protocols?<\/h3>\n<p>Yes \u2014 the four compounds target overlapping but mechanistically distinct nodes of mitochondrial \/ AMPK \/ NAD-axis biology and are commonly combined in studies that aims to dissect direct AMPK activation (AICAR) from peptide-class AMPK activation (<a href=\"https:\/\/medsbase.com\/ja\/mots-c\/\">MOTS-c<\/a>\uff09\u3001NAD\u524d\u99c6\u4f53\u7bc0\u7d04\uff08<a href=\"https:\/\/medsbase.com\/ja\/5-amino-1mq\/\">5-Amino-1MQ<\/a>\uff09\u3001\u76f4\u63a5\u7684\u306aNAD\u30d7\u30fc\u30eb\u88dc\u5145\uff08<a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD<sup>+<\/sup><\/a>\uff09\u3002\u307e\u305a\u5404\u6210\u5206\u3092\u500b\u5225\u306b\u518d\u69cb\u6210\u3057\u3066\u5b89\u5b9a\u6027\u3068\u6fc3\u5ea6\u306e\u6b63\u78ba\u6027\u3092\u78ba\u8a8d\u3057\u3001\u518d\u69cb\u6210\u5f8c\u306e\u30d0\u30a4\u30a2\u30eb\u3092\u4e00\u7dd2\u306b\u4fdd\u5b58\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u4f7f\u7528\u76f4\u524d\u306b\u6df7\u5408\u3057\u307e\u3059\u3002\u6700\u3082\u591a\u304f\u5831\u544a\u3055\u308c\u3066\u3044\u308b\u7d44\u307f\u5408\u308f\u305b\u306f\u3001AICAR + \u30e1\u30c8\u30db\u30eb\u30df\u30f3\uff08\u4e8c\u91cdAMPK\u6d3b\u6027\u5316\u3001\u7570\u306a\u308b\u4e0a\u6d41\u5206\u679d\uff09\u304a\u3088\u3073AICAR + \u30e9\u30d1\u30de\u30a4\u30b7\u30f3\uff08\u4e8c\u91cdmTORC1\u963b\u5bb3\u3001\u7570\u306a\u308b\u30e1\u30ab\u30cb\u30ba\u30e0\uff09\u3067\u3059\u3002 <\/p>\n<h3>\u30a2\u30ab\u30c7\u30b7\u30f3\uff08Acadesine\uff09\u306f\u306a\u305c\u81e8\u5e8a\u627f\u8a8d\u3092\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Acadesine (the clinical-trial name for AICAR) completed two large Phase III trials for cardioprotection in coronary artery bypass surgery (CABG) in the 1990s. The trials did not demonstrate statistically significant reductions in the primary composite endpoint (myocardial infarction, stroke, cardiovascular death), and the development programme was discontinued. AICAR remains a tool compound rather than an approved drug, although a number of academic groups have continued to investigate the cardioprotection paradigm and the broader AMPK-pathway pharmacology. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Compounds for AMPK and Metabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u7531\u6765\u30da\u30d7\u30c1\u30c9AMPK\u6d3b\u6027\u5316\u5264 \u2014 \u6700\u3082\u8fd1\u3044\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u30da\u30d7\u30c1\u30c9\u985e\u4f3c\u4f53<\/li>\n<li><a href=\"\/ja\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 \u9078\u629e\u7684NNMT\u963b\u5bb3\u5264 \u2014 \u76f8\u88dc\u7684\u306aNAD\u524d\u99c6\u4f53\u7bc0\u7d04\u30a2\u30d7\u30ed\u30fc\u30c1<\/li>\n<li><a href=\"\/ja\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 Oxidised dinucleotide coenzyme \u2014 direct NAD-pool supplementation studies<\/li>\n<li><a href=\"\/ja\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 \u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u7d50\u5408\u6027\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u6a19\u7684\u30da\u30d7\u30c1\u30c9<\/li>\n<li><a href=\"\/ja\/l-carnitine\/\"><strong>L-\u30ab\u30eb\u30cb\u30c1\u30f3<\/strong><\/a> \u2014 \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u9577\u9396\u8102\u80aa\u9178\u30b7\u30e3\u30c8\u30eb \u2014 \u4f75\u7528\u4f4e\u5206\u5b50<\/li>\n<li><a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 \u5168\u3066\u306e\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306e\u518d\u6eb6\u89e3\u306b\u5fc5\u8981 \u2014 \u7121\u83cc\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u5e0c\u91c8\u6db2<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u6a19\u6e96\u7684\u306a\u4f4e\u5206\u5b50AMPK\u6d3b\u6027\u5316\u5264\uff08ZMP\u3092\u4ecb\u3057\u305f\u7d30\u80de\u900f\u904e\u6027AMP\u985e\u4f3c\u4f53\uff09<br \/>\n\u2705 \u30a4\u30f3\u30b9\u30ea\u30f3\u975e\u4f9d\u5b58\u6027\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u53d6\u308a\u8fbc\u307f\u3092\u9aa8\u683c\u7b4b\u3078\u4fc3\u9032<br \/>\n\u2705 \u809d\u81d3\u3067\u306e\u7cd6\u65b0\u751f\u3001de-novo\u8102\u80aa\u5408\u6210\u3001\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u5408\u6210\u3092\u6291\u5236<br \/>\n\u2705 \u767a\u8868\u3055\u308c\u305f\u300c\u904b\u52d5\u6a21\u5023\u300d\u8868\u73fe\u578b\uff08Narkar et al. 2008\u3001Cell\uff09<br \/>\n\u2705 AMPK\u85ac\u7406\u5b66\u306e\u53c2\u7167\u5316\u5408\u7269 \u2014 MW 258.23\u3001CAS 2627-69-2<\/p>\n<p><strong>AICAR<\/strong> contains 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside compound.<\/p>","protected":false},"featured_media":71435,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6486,6487,6485,6488,6489,6484,6482],"class_list":["post-71431","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-acadesine","product_tag-aica-riboside","product_tag-aicar","product_tag-ampk-activator","product_tag-exercise-mimetic","product_tag-metabolic-research","product_tag-research-compound","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/71431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=71431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/71435"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=71431"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=71431"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=71431"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=71431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}